Lack of bromocriptine-induced reduction of predicted height in tall adolescents

Details

Serval ID
serval:BIB_0182EFA3C26C
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Lack of bromocriptine-induced reduction of predicted height in tall adolescents
Journal
Journal of Clinical Endocrinology and Metabolism
Author(s)
Schoenle  E. J., Theintz  G., Torresani  T., Prader  A., Illig  R., Sizonenko  P. C.
ISSN
0021-972X (Print)
Publication state
Published
Issued date
08/1987
Volume
65
Number
2
Pages
355-8
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Aug
Abstract
Fifteen girls and five boys with excessive predicted adult height (chronological age, 10.1-14.6 yr; bone age, 11.0-14.0 yr) were treated with bromocriptine (two doses; 2.5 mg/day) to reduce their final height. After a mean treatment period of 1.14 yr (range, 0.6-1.75 yr) we did not find a reduction of predicted adult height [difference, -0.5 +/- 3.5 (+/- SD) cm according to Bayley and Pinneau's tables (P = NS) and +0.2 +/- 2.5 (+/- SD) cm according to the method of Tanner (P = NS)]. Mean peak plasma GH concentrations after TRH administration before and during bromocriptine were 51.5 +/- 49.4 and 58.5 +/- 50.7 mU/L, respectively. The wide range of the GH values may be explained by physiological variation in this age group. After ingestion of 2.5 mg bromocriptine a significant increase in plasma GH occurred within 3 h in six adolescents tested. Our results do not support the concept that bromocriptine may reduce predicted adult height in tall adolescents by decreased GH secretion or acceleration of skeletal maturation.
Keywords
Adolescent Age Determination by Skeleton Body Height/*drug effects Bromocriptine/*therapeutic use Child Female Growth Hormone/blood Humans Male Thyrotropin-Releasing Hormone/diagnostic use
Pubmed
Web of science
Create date
25/01/2008 10:31
Last modification date
20/08/2019 12:23
Usage data